BioSpace News Archive

Lantheus Holdings, Inc. announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer and Jean-Claude Provost, MD has been named Chief Science Officer, effective May 28, 2024.

Precision Optics Corporation, Inc., a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its third quarter fiscal year 2024 for the period ended March 31, 2024.

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, reported financial and operating results for the first quarter ended March 31, 2024.

Extendicare Inc. reported results for the three months ended March 31, 2024.

Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.6 million for the first three months of 2024 and an operating loss of nearly $3.0 million for the period, as compared to total net sales for the same period last year of $11.0 million and an operating loss of $2.7 million.

Veracyte, Inc. a leading cancer diagnostics company, announced it will participate in the following investor conferences.

Centogene N.V. announced it has entered into a set of agreements with Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund in Saudi Arabia.

Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq;DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today highlighted recent corporate progress and reported financial results for the first quarter ended March 31, 2024.

Quest Diagnostics, a leader in diagnostic information services, announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.